Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 3,675.6	$ 2,261.4
Marketable securities	1,235.5	1,541.1
Accounts receivable, net	1,568.8	1,549.4
Due from anti-CD20 therapeutic programs	415.4	412.3
Inventory	1,375.0	1,351.5
Other current assets	1,495.5	740.8
Total current assets	9,765.8	7,856.5
Marketable securities	860.3	892.0
Property, plant and equipment, net	3,266.4	3,416.4
Operating lease assets	424.5	375.4
Intangible assets, net	2,008.9	2,221.3
Goodwill	5,741.2	5,761.1
Deferred tax asset	1,174.5	1,415.1
Investments and other assets	1,612.6	1,939.5
Total assets	24,854.2	23,877.3
Current liabilities:
Current portion of notes payable	0.0	999.1
Taxes payable	237.3	174.7
Accounts payable	383.2	589.2
Accrued expense and other	3,305.9	2,535.2
Total current liabilities	3,926.4	4,298.2
Notes payable	6,279.2	6,274.0
Deferred tax liability	328.9	694.5
Long-term operating lease liabilities	354.8	330.4
Other long-term liabilities	1,198.1	1,320.5
Total liabilities	12,087.4	12,917.6
Commitments, contingencies and guarantees
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	0.0	68.2
Accumulated other comprehensive income (loss)	(163.6)	(106.7)
Retained earnings	15,916.1	13,911.7
Treasury stock, at cost	(2,977.1)	(2,977.1)
Total Biogen Inc. shareholders’ equity	12,775.5	10,896.2
Noncontrolling interests	(8.7)	63.5
Total equity	12,766.8	10,959.7
Total liabilities and equity	$ 24,854.2	$ 23,877.3